Trial
NCT04847921
Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Colorado, Denver
Collaborators
—
Condition
Gram-Positive Bacterial Infections
Intervention
Dalbavancin
Why stopped
Delays in recruitment due to COVID-19 and higher than acceptable loss to followup.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-10-19